AOD-9604 vs Sermorelin
How AOD-9604 and Sermorelin compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
AOD-9604 and Sermorelin come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
AOD-9604 vs Sermorelin, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | AOD-9604 | Sermorelin |
|---|---|---|
| What it is | Synthetic 16-amino-acid fragment of human growth hormone (an hGH 176–191 analog) | Synthetic 29-amino-acid peptide — GHRH(1-29), the biologically active fragment of human growth hormone-releasing hormone |
| Class / category | Incretin / metabolic | GH secretagogues |
| Evidence tier | Human (controlled) · Mixed | Human (controlled) · Mixed |
| Studied / approved for | Fat loss / weight reduction; Obesity | Diagnosing growth hormone deficiency (GHRH stimulation test); Age-related decline in growth hormone / body composition; Adult and childhood growth hormone deficiency |
| US regulatory status (2026) | research use only (as of Jul 2026) | withdrawn (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 0 | 27 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | AOD-9604 has an unusually good human safety record for a research peptide: it was well tolerated in clinical obesity trials, with no significant effect on blood sugar or IGF-1. That said, long-term human data are thin, and the products sold today are unregulated research chemicals whose purity and dose accuracy vary from vendor to vendor. | Sermorelin was generally well tolerated across its years as an approved drug. The most common issues are injection-site reactions (redness, swelling, pain), with flushing, headache, and occasional dizziness or nausea also reported. Because sermorelin raises your own GH and IGF-1, it carries the theoretical growth-hormone-axis caution shared by all GH therapies — it is not for use in active cancer or pregnancy — and there is no long-term human safety data for the anti-aging use. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
AOD-9604 vs Sermorelin: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.
References
- 1.AOD-9604 (CID 71300630) — compound record, PubChem (National Library of Medicine)
- 2.AOD-9604 — indexed research (PubMed, National Library of Medicine)
- 3.AOD-9604 — registered clinical studies (ClinicalTrials.gov)
- 4.FDA — Drugs (approval status & compounding information)
- 5.Global Drug Reference Online (GlobalDRO) — prohibited-substance status in sport
- 6.Sermorelin — indexed human research (PubMed, National Library of Medicine)